Administration of the cardiacglycoside digoxin with the potential hypoxia-inducible factor 1-α(HIF1-α) and angiogenesis inhibitory effects could synergisticallyaugment mEHT-mediated tumor damage and reduce tissue hypoxia signalingand consequent vascular recovery in mEHT-treated TNBC tumors. The gene discussed is HIF1A; the disease is neoplasm.